Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Protagonist Therapeutics (PTGX) has disclosed Long-Term Deferred Tax for 3 consecutive years, with $1.1 million as the latest value for Q1 2020.

  • Quarterly Long-Term Deferred Tax rose 126.36% to $1.1 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2020, up 126.36% year-over-year, with the annual reading at $1.4 million for FY2019, 117.78% up from the prior year.
  • Long-Term Deferred Tax hit $1.1 million in Q1 2020 for Protagonist Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $2.1 million in Q3 2019 to a low of $478000.0 in Q1 2019.
  • Historically, Long-Term Deferred Tax has averaged $1.3 million across 3 years, with a median of $1.3 million in 2019.
  • Biggest five-year swings in Long-Term Deferred Tax: surged 117.78% in 2019 and later soared 126.36% in 2020.
  • Year by year, Long-Term Deferred Tax stood at $658000.0 in 2018, then soared by 117.78% to $1.4 million in 2019, then dropped by 24.49% to $1.1 million in 2020.
  • Business Quant data shows Long-Term Deferred Tax for PTGX at $1.1 million in Q1 2020, $1.4 million in Q4 2019, and $2.1 million in Q3 2019.